Verastem Net Income
| VSTM Stock | USD 6.17 0.24 3.74% |
As of the 30th of January, Verastem has the Coefficient Of Variation of (2,951), variance of 28.99, and Risk Adjusted Performance of (0.02). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Verastem, as well as the relationship between them. Please validate Verastem market risk adjusted performance and treynor ratio to decide if Verastem is priced more or less accurately, providing market reflects its prevalent price of 6.17 per share. Given that Verastem has information ratio of (0.05), we advise you to double-check Verastem's current market performance to make sure the company can sustain itself at a future point.
Verastem Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 31.4682 | Revenue | Earnings Share (4.28) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -117.6 M | -111.7 M | |
| Net Loss | -117.6 M | -111.7 M | |
| Net Loss | -66.4 M | -69.8 M | |
| Net Loss | (3.29) | (3.46) | |
| Net Income Per E B T | 1.15 | 1.10 |
Verastem | Net Income | Build AI portfolio with Verastem Stock |
Evaluating Verastem's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Verastem's fundamental strength.
Latest Verastem's Net Income Growth Pattern
Below is the plot of the Net Income of Verastem over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Verastem financial statement analysis. It represents the amount of money remaining after all of Verastem operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Verastem's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verastem's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (130.64 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Verastem Net Income Regression Statistics
| Arithmetic Mean | (69,692,937) | |
| Coefficient Of Variation | (57.92) | |
| Mean Deviation | 30,162,757 | |
| Median | (67,802,000) | |
| Standard Deviation | 40,366,647 | |
| Sample Variance | 1629.5T | |
| Range | 148.4M | |
| R-Value | (0.83) | |
| Mean Square Error | 544.3T | |
| R-Squared | 0.69 | |
| Significance | 0.000039 | |
| Slope | (6,625,040) | |
| Total Sum of Squares | 26071.5T |
Verastem Net Income History
Other Fundumenentals of Verastem
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Verastem Net Income component correlations
Verastem Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Verastem is extremely important. It helps to project a fair market value of Verastem Stock properly, considering its historical fundamentals such as Net Income. Since Verastem's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Verastem's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Verastem's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Verastem diversify its offerings? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Verastem data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.28) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Verastem's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Verastem 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Verastem's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Verastem.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Verastem on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Verastem or generate 0.0% return on investment in Verastem over 90 days. Verastem is related to or competes with Regenxbio, Absci Corp, MoonLake Immunotherapeuti, Kalvista Pharmaceuticals, Prothena Plc, Ventyx Biosciences, and Olema Pharmaceuticals. Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the ... More
Verastem Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Verastem's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Verastem upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 29.79 | |||
| Value At Risk | (6.80) | |||
| Potential Upside | 5.83 |
Verastem Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Verastem's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Verastem's standard deviation. In reality, there are many statistical measures that can use Verastem historical prices to predict the future Verastem's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.57) | |||
| Treynor Ratio | 0.8064 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Verastem's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Verastem January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.8164 | |||
| Mean Deviation | 3.76 | |||
| Coefficient Of Variation | (2,951) | |||
| Standard Deviation | 5.38 | |||
| Variance | 28.99 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.57) | |||
| Treynor Ratio | 0.8064 | |||
| Maximum Drawdown | 29.79 | |||
| Value At Risk | (6.80) | |||
| Potential Upside | 5.83 | |||
| Skewness | 0.2338 | |||
| Kurtosis | 5.1 |
Verastem Backtested Returns
Verastem owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.12, which indicates the firm had a -0.12 % return per unit of risk over the last 3 months. Verastem exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Verastem's Variance of 28.99, coefficient of variation of (2,951), and Risk Adjusted Performance of (0.02) to confirm the risk estimate we provide. The entity has a beta of -0.24, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Verastem are expected to decrease at a much lower rate. During the bear market, Verastem is likely to outperform the market. At this point, Verastem has a negative expected return of -0.63%. Please make sure to validate Verastem's treynor ratio and day typical price , to decide if Verastem performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.47 |
Modest reverse predictability
Verastem has modest reverse predictability. Overlapping area represents the amount of predictability between Verastem time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Verastem price movement. The serial correlation of -0.47 indicates that about 47.0% of current Verastem price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.47 | |
| Spearman Rank Test | -0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 0.46 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Verastem Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Verastem reported net income of (130.64 Million). This is 138.28% lower than that of the Biotechnology sector and 286.5% lower than that of the Health Care industry. The net income for all United States stocks is 122.88% higher than that of the company.
Verastem Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Verastem's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Verastem could also be used in its relative valuation, which is a method of valuing Verastem by comparing valuation metrics of similar companies.Verastem is currently under evaluation in net income category among its peers.
Verastem ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verastem's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verastem's managers, analysts, and investors.Environmental | Governance | Social |
Verastem Institutional Holders
Institutional Holdings refers to the ownership stake in Verastem that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Verastem's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Verastem's value.| Shares | Vivo Capital, Llc | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | Stonepine Capital Management Llc | 2025-06-30 | 1.4 M | Foresite Capital Management Vi Llc | 2025-06-30 | 1.3 M | Geode Capital Management, Llc | 2025-06-30 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.1 M | Polar Capital Holdings Plc | 2025-06-30 | 1000 K | Logos Global Management Lp | 2025-06-30 | 1000 K | Soleus Capital Management, L.p. | 2025-06-30 | 935.9 K | Rtw Investments, Llc | 2025-06-30 | 4.3 M | Balyasny Asset Management Llc | 2025-06-30 | 4.2 M |
Verastem Fundamentals
| Return On Equity | -28.89 | ||||
| Return On Asset | -0.66 | ||||
| Operating Margin | (3.62) % | ||||
| Current Valuation | 421.01 M | ||||
| Shares Outstanding | 75.32 M | ||||
| Shares Owned By Insiders | 0.87 % | ||||
| Shares Owned By Institutions | 87.66 % | ||||
| Number Of Shares Shorted | 17.12 M | ||||
| Price To Earning | (3.02) X | ||||
| Price To Book | 15.35 X | ||||
| Price To Sales | 36.09 X | ||||
| Revenue | 10 M | ||||
| Gross Profit | 11.39 M | ||||
| EBITDA | (125.86 M) | ||||
| Net Income | (130.64 M) | ||||
| Cash And Equivalents | 94.31 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 42.25 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 4.87 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (104.77 M) | ||||
| Short Ratio | 8.15 X | ||||
| Earnings Per Share | (4.28) X | ||||
| Price To Earnings To Growth | (1.89) X | ||||
| Target Price | 16.13 | ||||
| Number Of Employees | 78 | ||||
| Beta | 0.44 | ||||
| Market Capitalization | 482.8 M | ||||
| Total Asset | 101.54 M | ||||
| Retained Earnings | (955.53 M) | ||||
| Working Capital | 63.99 M | ||||
| Current Asset | 110.84 M | ||||
| Current Liabilities | 10.11 M | ||||
| Net Asset | 101.54 M |
About Verastem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verastem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verastem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verastem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Verastem diversify its offerings? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Verastem data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.28) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Verastem's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.